Dr. Daniel C. Danila

Dr. Daniel C. Danila, MD, is a leading figure in genitourinary medical oncology at Memorial Sloan Kettering Cancer Center (MSKCC), specializing in prostate cancer. A graduate of Carol Davila University of Medicine and Pharmacy in Bucharest, Romania, he completed his Internal Medicine residency at Massachusetts General Hospital followed by a Hematology/Oncology fellowship at MSKCC. Board-certified in both Internal Medicine and Medical Oncology, he serves as an Associate Attending Physician and part of the multidisciplinary team ranked among the nation’s best for Urology Cancer Care. He provides individualized treatment plans—including novel hormonal agents and biologics—supported by advanced diagnostic methods and offers care both in-person and via telehealth.

He is widely recognized for his translational research aimed at accelerating laboratory discoveries into clinical practice. Dr. Danila leads work on circulating tumor cells (CTCs) as biomarkers to predict androgen receptor signaling response, drawing on funding from the Department of Defense and ASCO. His lab also studies integration of PSMA PET imaging in prostate cancer management, helping inform early detection and treatment decisions. Dr. Danila has received ASCO Young Investigator and Merit Awards, along with a prestigious Physician Research Training Award, recognizing his leadership in prostate cancer biomarker development.

In addition to his clinical and scientific achievements, he is a national voice in prostate cancer care and research. He has authored numerous peer-reviewed studies and contributes to clinical guideline development through SWOG and MSK’s faculty efforts. He frequently presents at major conferences and provides expert perspectives on immunotherapy and imaging advances in prostate cancer. Through his integrated roles in patient-centered care, biomarker-driven discovery, and professional mentorship, Dr. Danila is regarded as a leading expert shaping the future of prostate cancer treatment.